论文部分内容阅读
目的:评价趋化因子受体4(CXCR4)联合P504S或P63蛋白在前列腺良、恶性疾病诊断和鉴别诊断中的应用价值,为前列腺疾病的诊断、鉴别诊断提供理论依据。方法:采用EnVision两步免疫组织化学方法,检测40例未经任何抗癌治疗的前列腺癌(PCa)和30例良性前列腺增生(BPH)石蜡标本中P504S、CXCR4和P63蛋白的表达情况,结合临床分析CXCR4与PCa转移特征相关性。结果:在40例PCa中,CXCR4蛋白表达阳性率为82.5%(33/40),P504S阳性率为92.5%(37/40),P63蛋白表达阳性率为5%(2/40)。30例BPH组织中,P63表达均为阳性,P504S阳性率为3.3%(1/30),而CXCR4阳性率16.7%(5/30)。P504S联合P63对PCa的诊断正确率要高于CXCR4+P63和P504S+CXCR4。PCa中CXCR4表达与癌转移特征相关性具有统计学差异(P<0.05)。结论:P504S、CXCR4及P63对良、恶性前列腺病变的诊断及鉴别诊断都有一定的参考作用。虽然CXCR4单独应用于诊断特异性差,诊断准确率相对较低,但CXCR4联合P504S或P63诊断准确率高,对前列腺疾病的良、恶性鉴别诊断有重要临床应用价值。
Objective: To evaluate the value of chemokine receptor 4 (CXCR4) combined with P504S or P63 protein in the diagnosis and differential diagnosis of benign and malignant prostatic diseases, and to provide a theoretical basis for the diagnosis and differential diagnosis of prostatic diseases. Methods: The EnVision two-step immunohistochemistry was used to detect the expression of P504S, CXCR4 and P63 protein in 40 cases of prostate cancer (PCa) and 30 cases of benign prostatic hyperplasia (BPH) without any anti-cancer therapy. Combined with clinical The correlation between CXCR4 and PCa metastasis characteristics was analyzed. Results: The positive rate of CXCR4 protein was 82.5% (33/40), the positive rate of P504S was 92.5% (37/40) and the positive rate of P63 protein was 5% (2/40) in 40 cases of PCa. In 30 cases of BPH, the expression of P63 was positive, the positive rate of P504S was 3.3% (1/30), while the positive rate of CXCR4 was 16.7% (5/30). P504S combined with P63 on PCa diagnostic accuracy rate is higher than CXCR4 P63 and P504S CXCR4. The correlation between the expression of CXCR4 and the metastasis of PCa was statistically significant (P <0.05). Conclusion: P504S, CXCR4 and P63 have certain reference value for the diagnosis and differential diagnosis of benign and malignant prostatic lesions. Although CXCR4 is used alone in diagnosis of poor specificity and relatively low diagnostic accuracy, the diagnostic accuracy of CXCR4 in combination with P504S or P63 is of high diagnostic value, which has important clinical value in the differential diagnosis of benign and malignant prostatic diseases.